Addendum
Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31
Report documents
-
Addendum
Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31
Additional information
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- G23-20
- Commission
- Commission awarded on 09.08.2023 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If, in the course of the discussions on a commission of the GBA, a need for further revision arises, IQWiG submits an addendum. The GBA decides on the number of patients in the SHI target population.
Connected Projects
-
Dossier assessment
Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31
Status: Commission completed